Why Organon (OGN) Is Surging as Buyout Interest Gains Traction

Organon & Co. (NYSE:OGN) is one of the 10 potential takeover targets with strong price momentum. Around April 10–13, 2026, reports emerged that Sun Pharmaceutical Industries had submitted a binding offer to acquire the company in a deal valued at roughly $10 billion to $12 billion. The market reaction was immediate.

Organon shares surged about 28% in a single session and had risen nearly 39% over the week following the reports, marking one of the sharpest moves tied to takeover speculation this year.

Why Organon (OGN) Is Surging as Buyout Interest Gains Traction

pathdoc/Shutterstock.com

That reaction reflects how the market is pricing in the strategic value of the business rather than its current financial profile. Organon, which was spun off from Merck & Co. in 2021, has a portfolio spanning women’s health, biosimilars, and established medicines, including contraceptive and fertility products such as Nexplanon and NuvaRing. The company’s scale and product base make it a plausible target for a strategic buyer looking to expand internationally or deepen exposure to women’s health.

Organon & Co. (NYSE:OGN) is a global healthcare company focused on women’s health, biosimilars, and a portfolio of established medicines.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.